New hope to halt childhood bone disease progression
NCT ID NCT05419050
Summary
This study tested whether a medication called denosumab could slow or stop the progression of fibrous dysplasia, a rare bone disease, in children. Fifteen children aged 4 to 14 received denosumab injections every four weeks for nearly a year. Researchers measured changes in bone lesions, strength, mobility, pain, and quality of life to see if the treatment was effective and safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROUS DYSPLASIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.